Erste Group analyst Hans Engel resumed coverage of Regeneron with a Buy rating, removing the stock from Under Review, following the company’s successful phase 3 study in COPD. The company’s shares are "moderately valued in view of the very positive growth prospects," said the firm, which thinks Dupixent has the potential to "strongly expand" sales in the coming years.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
- Immuneering appoints Harold Brakewood as CBO
- Regeneron Pharmaceuticals, Sonoma Biotherapeutics announce collaboration
- Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
- SVB Securities upgrades Regeneron to Outperform, sees positive drivers ahead